Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO2020115368 - PROCÉDÉ POUR DÉTERMINER LA RÉACTIVITÉ CHEZ UN PATIENT À UN TRAITEMENT PAR INTERFÉRON DE TYPE 1 ET UTILISATION D'INTERFÉRON DE TYPE 1 POUR TRAITER UN PATIENT AYANT UN POLYMORPHISME MONONUCLÉOTIDIQUE SPÉCIFIÉ

Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

[ EN ]

Claims

1. A method for determining a patient’s responsiveness to a treatment with type I interferon, optionally concomitant with a corticosteroid, the method comprising

- determining the presence or absence of single nucleotide polymorphism (SNP) rs9984273 (C/T) in subunit 2 of the interferon alpha and beta receptor (IFNAR2) in chromosome 21 from a sample obtained from the patient, and

- classifying the patient on the grounds of the presence or absence of said SNP, wherein

i) the presence of said SNP indicates responsiveness to the treatment comprising type I interferon concomitant with or without the corticosteroid, or ii) the absence of said SNP indicates non responsiveness to the treatment comprising type I interferon concomitant with the corticosteroid and modest responsiveness to the treatment comprising type I interferon without concomitant the corticosteroid.

2. The method according to claim 1 , wherein the presence of said SNP is determined by detecting a SNP rs9984273 (C/T) and/or a SNP in linkage disequilibrium with the SNP rs9984273 (C/T) in IFNAR2.

3. The method according to claim 1 or 2, wherein type I interferon is selected from interferon beta, interferon alpha and any subtypes of them.

4. The method according to claim 3, wherein type I interferon is interferon beta-1 a.

5. The method according to any of the preceding claims, wherein the corticosteroid is selected from the group of glucocorticoids, preferably hydrocortisone, prednisone, prednisolone, methylprednisolone, betametatsone and/or dexamethasone.

6. The method according to any of the preceding claims, wherein the patient’s responsiveness is determined to the treatment of a disease or a disorder selected from the group comprising

- vascular-endothelial diseases,

- acute respiratory distress syndrome (ARDS), systemic inflammatory response syndrome (SIRS), or other traumatic conditions,

- ischemia-reperfusion injury,

- ischemic pre-conditioning prior to major vascular or cardiac surgery and organ transplantation,

- acute pancreatitis,

- acute kidney injury,

- multi-organ failure (MOF),

- severe respiratory or haemorrhagic viral infections,

- multiple sclerosis (MS),

- hairy cell leukaemia, malignant melanoma, follicular lymphoma, condylomata acuminate, AIDS related Kaposi’s Sarcoma, chronic hepatitis C, acute hepatitis C and chronic hepatitis B.

7. The method according to any of the preceding claims, wherein the patient with the presence of said SNP in the sample has the survival probability of > 0.8, preferably > 0.85 or more preferably > 0.9 with said therapy.

8. A composition comprising type I interferon as an active ingredient for use in in a method of the treatment of a disease or a disorder selected from

- vascular-endothelial diseases,

- acute respiratory distress syndrome (ARDS), systemic inflammatory response syndrome (SIRS), or other traumatic conditions,

- ischemia-reperfusion injury,

- ischemic pre-conditioning prior to major vascular or cardiac surgery and organ transplantation,

- acute pancreatitis,

- acute kidney injury,

- multi-organ failure (MOF),

- severe respiratory or haemorrhagic viral infections,

- multiple sclerosis (MS),

- hairy cell leukaemia, malignant melanoma, follicular lymphoma, condylomata acuminate, AIDS related Kaposi’s Sarcoma, chronic hepatitis C, acute hepatitis C and chronic hepatitis B,

in a patient, wherein said patient has a single nucleotide polymorphism (SNP) rs9984273 (C/T) and/or a SNP in linkage disequilibrium with the SNP rs9984273 (C/T), in subunit 2 of the interferon alpha and beta receptor (IFNAR2) in chromosome 21.

9. A composition comprising type I interferon as an active ingredient for use in a method of the treatment of the disease or the disorder according to claim 8, wherein the composition is used concomitant with a corticosteroid.

10. A composition comprising type I interferon as an active ingredient for use in a method of the treatment of the disease or the disorder according to claim 8 or 9, wherein the method comprises the step of determining the presence of single nucleotide polymorphism (SNP) rs9984273 (C/T) in subunit 2 of the interferon alpha and beta receptor (IFNAR2) in chromosome 21 from a sample obtained from the patient.

11. A composition comprising type I interferon as an active ingredient for use in a method of the treatment of the disease or the disorder according to any of the preceding claims 8 - 10, wherein type I interferon is selected from interferon beta, interferon alpha and any subtypes of them.

12. A composition comprising type I interferon as an active ingredient for use in a method of the treatment of the disease or the disorder according to any of the preceding claims 8 11 , wherein the corticosteroid is selected from the group of glucocorticoids, preferably hydrocortisone, prednisone, prednisolone, methylprednisolone, betametatsone and/or dexamethasone.

13. A composition comprising type I interferon as an active ingredient for use in a method of the treatment of the disease or the disorder according to any of the preceding claims 8 - 12, wherein type I interferon comprises interferon beta-1 a.

14. Use of a single nucleotide polymorphism (SNP) rs9984273 (C/T) and/or a SNP in linkage disequilibrium with the SNP rs9984273 (C/T), in subunit 2 of the interferon alpha and beta receptor (IFNAR2) in chromosome 21 , for a marker in a selection of patients to a treatment comprising type I interferon and optionally concomitant with a corticosteroid.

15. Use according to claims 14, wherein the patient has a disease or a disorder selected from

- vascular-endothelial diseases,

- acute respiratory distress syndrome (ARDS), systemic inflammatory response syndrome (SIRS), or other traumatic conditions,

- ischemia-reperfusion injury,

- ischemic pre-conditioning prior to major vascular or cardiac surgery and organ transplantation,

- acute pancreatitis,

- acute kidney injury,

- multi-organ failure (MOF),

- severe respiratory or haemorrhagic viral infections,

- multiple sclerosis (MS),

- hairy cell leukaemia, malignant melanoma, follicular lymphoma, condylomata acuminate, AIDS related Kaposi’s Sarcoma, chronic hepatitis C, acute hepatitis C and chronic hepatitis B.